4‐[8‐(hydroxyamino)‐8‐oxooctanamido]benzoic acid | 1262297-32-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4‐[8‐(hydroxyamino)‐8‐oxooctanamido]benzoic acid
• 英文别名: 4-[[8-(Hydroxyamino)-8-oxooctanoyl]amino]benzoic acid
• CAS: 1262297-32-4
• 化学式: C₁₅H₂₀N₂O₅
• 分子量: 308.334
• InChiKey: MKGNGPUNDMYALB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  116
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2,9-氧杂环壬烷二酮 在 水 、 氯甲酸乙酯 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 25.25h， 生成 4‐[8‐(hydroxyamino)‐8‐oxooctanamido]benzoic acid
  参考文献：
  名称：

  [EN] METAL COMPLEXES HAVING DUAL HISTONE DEACETYLASE INHIBITORY AND DNA-BINDING ACTIVITY
  [FR] COMPLEXES MÉTALLIQUES AYANT UNE DOUBLE ACTIVITÉ INHIBITRICE D'HISTONE DÉSACÉTYLASE ET DE LIAISON À L'ADN

  摘要：

  公开号：

  WO2011006908A3

文献信息

• Soft drug inhibitors for the epigenetic targets lysine‐specific demethylase 1 and histone deacetylases
  作者：Johannes Seitz、Marina Auth、Tony Prinz、Mirjam Hau、Pavlos Tzortzoglou、Johannes Schulz‐Fincke、Karin Schmidtkunz、Adina A. Baniahmad、Dominica Willmann、Eric Metzger、Lutz Hein、Sebastian Preissl、Roland Schüle、Manfred Jung

  DOI：10.1002/ardp.202400450

  日期：2024.10

  Epigenetic modulators such as lysine‐specific demethylase 1 (LSD1) and histone deacetylases (HDACs) are drug targets for cancer, neuropsychiatric disease, or inflammation, but inhibitors of these enzymes exhibit considerable side effects. For a potential local treatment with reduced systemic toxicity, we present here soft drug candidates as new LSD1 and HDAC inhibitors. A soft drug is a compound that is degraded in vivo to less active metabolites after having achieved its therapeutic function. This has been successfully applied for corticosteroids in the clinic, but soft drugs targeting epigenetic enzymes are scarce, with the HDAC inhibitor remetinostat being the only example. We have developed new methyl ester‐containing inhibitors targeting LSD1 or HDACs and compared the biological activities of these to their respective carboxylic acid cleavage products. In vitro activity assays, cellular experiments, and a stability assay identified potent HDAC and LSD1 soft drug candidates that are superior to their corresponding carboxylic acids in cellular models.